← Eichor
Study identifier: NCT06686979 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

PDO Based Drug Sensitive Test in R/M SGC

Condition: Salivary Gland Cancers · Patient Derived Organoid · Drug Sensitive Test in Vitro  ·  Sponsor: Huashan Hospital

PhaseN/A
Planned participants40
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

To evaluate the consistency of drug efficacy between the clinical systemic treatment and drug sensitive test based on patient-derived organoid in R/M SGC patients, using a prospective and multicenter observational study to increase the generalizability and reliability of research conclusion.

This description comes directly from the study's public registry record.

Talk to the study team

Lai-ping Zhong, MD, PhD  ·  +862152888915  ·  zhonglp@hotmail.com

Tong-chao Zhao, MD, PhD  ·  +862152889999  ·  961497591@qq.com

Always discuss trial participation with your own doctor first.

Locations (2)

Huashan Hospital, Fudan UniversityShanghai, Shanghai Municipality, ChinaActive Not Recruiting
Huashan Hospital, Fudan UniversityShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06686979